Products
Pre-made Pepinemab benchmark antibody ( Whole mAb, anti-SEMA4D therapeutic antibody, Anti-A8/BB18/C9orf164/CD100/COLL4/GR3/M-sema-G/SEMAJ/coll-4 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-437
Pre-Made Pepinemab biosimilar, Whole mAb, Anti-SEMA4D Antibody: Anti-A8/BB18/C9orf164/CD100/COLL4/GR3/M-sema-G/SEMAJ/coll-4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pepinemab is a humanised IgG4 monoclonal antibody against the semaphorin 4D (SEMA4D; CD100), being developed by Vaccinex for the treatment of multiple cancers, Alzheimer's disease and Huntington's disease.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-437-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Pepinemab biosimilar, Whole mAb, Anti-SEMA4D Antibody: Anti-A8/BB18/C9orf164/CD100/COLL4/GR3/M-sema-G/SEMAJ/coll-4 therapeutic antibody |
| INN Name | Pepinemab |
| Target | SEMA4D |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Bristol-Myers Squibb;Children's Oncology Group;Emory University;Merck KGaA;National Cancer Institute (USA);Teva Pharmaceutical Industries;UCLAs Jonsson Comprehensive Cancer Center;Vaccinex |
| Conditions Approved | na |
| Conditions Active | Huntington's disease;Non-small cell lung cancer;Osteosarcoma;Solid tumours;Colorectal cancer;Head and neck cancer;Malignant melanoma;Pancreatic cancer |
| Conditions Discontinued | Multiple sclerosis |
| Development Tech | na |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
Facebook
LinkedIn
Twitter
<